Zenas BioPharma, Inc. reported $1.0M of revenue over the trailing twelve months, −93% on the year before. 6 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.0M (to Q2 2026). Net income: −$484M, trailing twelve months to Q2 2026. Free cash flow: −$226M, trailing twelve months to Q2 2026. EPS: −$9.62, trailing twelve months to Q2 2026.

ZBIOZenas BioPharma, Inc.

Healthcare

$27.24+44% 1Y

$27.24

$15.2052 weeks$43.17

ZBIO as reported

Zenas BioPharma, Inc. reported $1.0M of revenue over the trailing twelve months, −93% on the year before. 6 reported series are charted on this page, each one as filed.

$1.0M

Revenue, trailing twelve months · to Q2 2026 · −93% against the twelve months before

Net income: −$484M
Net income · +174% year on year · trailing twelve months to Q2 2026
Free cash flow: −$226M
Free cash flow · +52% year on year · trailing twelve months to Q2 2026
EPS: −$9.62
EPS · −197% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ZBIO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.0M	−93%	Q2 2026
Net income	−$484M	+174%	Q2 2026
EPS	−$9.62	−197%	Q2 2026
ROE	−144%	n/a	Q2 2026
ROA	−71%	n/a	Q2 2026
Free cash flow	−$226M	+52%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.